Identification of Anaplastic Lymphoma Kinase Fusions in Renal Cancer Large-Scale Immunohistochemical Screening by the Intercalated Antibody-Enhanced Polymer Method

摘要: BACKGROUND: Several promising molecular-targeted drugs are used for advanced renal cancers. However, complete remission is rarely achieved, because none of the targets a key molecule that specific to cancer, or associated with “oncogene addiction” (dependence on one few oncogenes cell survival) cancer. Recently, an anaplastic lymphoma kinase (ALK) fusion, vinculin-ALK, has been reported in pediatric carcinoma (RCC) cases who have history sickle trait. In this context, ALK inhibitor therapy would constitute therapeutic advance, as previously demonstrated lung inflammatory myofibroblastic tumors, and large lymphomas. METHODS: Anti-ALK immunohistochemistry was screen 355 tumor tissues, using intercalated antibody-enhanced polymer (iAEP) method. The cohort consisted 255 clear RCCs, 32 papillary 34 chromophobe 6 collecting duct carcinomas, 10 unclassified sarcomatoid 12 other tumors. RESULTS: Two patients (36- 53-year-old females) were positive determined by iAEP immunohistochemistry. Using 5′- rapid amplification complementary DNA ends, we detected TPM3-ALK EML4-ALK these tumors. results study confirmed fluorescence situ hybridization assays. 2 ALK-positive RCCs (mixed features papillary, mucinous cribriform, solid patterns rhabdoid cells) subtype. They comprised 2.3% non–clear (2 88) 3.7% nonchromophobe 54). CONCLUSIONS: The indicate fusions also exist adult RCC without uncommon backgrounds. These findings confirm potential selected RCC. Cancer 2012. © 2012 American Society.